The 308nm excimer light has demonstrated efficacy in a growing list of dermatologic conditions. A 2024 comprehensive review summarized its therapeutic applications:

Condition	Therapeutic Effect	Evidence Level
Vitiligo	Induces melanocyte stem cell differentiation; stimulates melanin production and melanocyte migration; 75% repigmentation when combined with topical immunosuppressants	First-line for localized disease (<10% BSA)
Psoriasis	Effective for difficult-to-treat subtypes (palmoplantar pustular, scalp, nail); option in refractory cases; >50% achieve full remission	Well-established
Alopecia Areata	Achieves cosmetically acceptable hair regrowth (>50%); useful in resistant cases; decreases SALT score	Supported by multiple studies
Atopic Dermatitis	Effective for localized disease (<20% BSA); decreases erythema, pruritus, excoriation, and lichenification; improves quality of life	Preliminary clinical trial evidence
Mycosis Fungoides (CTCL)	Useful in early stages (IA, IIA); complete clinical response in 76.3% of cases	Case series evidence
Granuloma Annulare	Complete remission seen in combination with topical/systemic corticosteroids	Case reports
Nodular Prurigo	Complete remission in resistant cases	Clinical experience
Localized Scleroderma (Morfea)	Inactivates lesions and decreases lesion size	Emerging evidence
Genital Lichen Sclerosis	Effective for photo-resistant disease	Case series

Vitiligo: The Most Extensively Studied Indication

Vitiligo serves as the paradigm for 308nm excimer light therapy, with the most robust evidence base.

Key Clinical Findings:

Indication: Localized vitiligo affecting <10% body surface area, including both non-segmental and segmental types.
Treatment Protocol: 2–3 sessions weekly, minimum 48 hours between treatments, for 4–36 weeks.
Predictor of Response: The total number of treatment sessions is the most important predictor of repigmentation.
Onset of Response: Initial repigmentation typically appears within the first 8 treatments; excellent repigmentation (≥75%) in 50% of patients at 6 months.

Efficacy Compared to Other Modalities:

A 2016 meta-analysis of seven randomized controlled trials (390 patients) found:

No significant difference between 308nm excimer laser and 308nm excimer lamp for ≥75% or ≥50% repigmentation
No significant difference between 308nm excimer laser and NB-UVB for 100% or ≥75% repigmentation
More patients achieved ≥50% repigmentation with excimer laser than NB-UVB

A 2025 systematic review reaffirmed that the 308nm excimer lamp provides superior repigmentation outcomes compared to NB-UVB and demonstrates comparable efficacy to the excimer laser.

Anatomical Variation in Response:

Best response: Face, neck, trunk, proximal extremities
Poorest response: Hands, feet, elbows, knees (bony prominences and acral sites).

Combination Therapy:

Combining excimer light with topical tacrolimus significantly improves outcomes, with studies showing >75% repigmentation in combination therapy -2 -5. This is particularly valuable for resistant anatomical sites and segmental vitiligo.

New Insights: ANA Status Does Not Affect Outcomes

A 2026 cohort study of 86 vitiligo patients investigated whether antinuclear antibody (ANA) positivity—common in autoimmune conditions—influenced response to 308nm therapy. The results were reassuring:

No significant differences in cumulative treatment doses, adverse events, or occurrence of new autoimmune conditions between ANA-positive and ANA-negative patients
ANA-positive lesions on the face/neck more frequently achieved moderate repigmentation (50-74%) but were slightly less likely to reach excellent repigmentation (≥75%)
Conclusion: ANA positivity does not significantly affect the efficacy or safety of 308nm excimer light therapy.

Psoriasis: Targeted Clearance of Stubborn Plaques

308nm excimer light is particularly valuable for localized plaque psoriasis that has failed topical therapy.

Indication: Plaque psoriasis affecting <10% BSA; difficult-to-treat sites (scalp, palms, soles, nails).
Treatment Protocol: 2–3 sessions weekly; 20 sessions per typical course .
Response: >50% of patients achieve full remission.
Mechanism: Induces T-cell apoptosis and reduces keratinocyte hyperproliferation .

Atopic Dermatitis: Emerging Evidence for Localized Disease

A 2023 clinical study provided preliminary evidence for 308nm excimer light in moderate, localized atopic dermatitis -8.

Study Design: 25 Korean adults with bilateral, symmetric eczematous lesions; test lesions treated twice weekly for 4 weeks
Results: Statistically significant improvement in AD severity (p<0.001) and skin barrier function (p<0.01) in treated vs. control lesions
Conclusion: 308nm excimer light improves symptoms and skin barrier function in moderately localized AD.

The 308nm excimer light of dermatologic conditions

Get the latest price?